Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study

Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study

BackgroundThis study examines the humoral and cellular response in multiple sclerosis (MS) patients on anti-CD20 therapy before and after the 1st to 4th BNT162b2 mRNA SARS-CoV-2 vaccination and the relationship with breakthrough infection.MethodsParticipants with McDonald 2017 MS that were treated w...

Full description

Bibliographic Details
Main Authors: Frederik Novak, Anna Christine Nilsson, Emil Birch Christensen, Caroline Louise Stougaard, Mike Bogetofte Barnkob, Dorte K. Holm, Agnes Hauschultz Witt, Keld-Erik Byg, Isik S. Johansen, Christian Nielsen, Tobias Sejbaek
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
anti-CD20
mRNA vaccination vulnerable population
SARS-CoV-2
ocrelizumab concentration
breakthrough infection
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1432348/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1432348/full

Similar Items